288 completed, 83 recruiting, 76 unknown, 24 not yet recruiting. 129 Phase 4, 112 Phase 3, 103 Phase 2, 97 Phase 1, 43 Not applicable.
Follow empagliflozin: new trials by email Literature Review of empagliflozin trials Research Report on empagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction Jardiance, non-SGLT2 inhibitors - Heart Failure of Reduced Ejection Fraction (HFrEF) | Not yet recruiting | Boehringer Ingelheim | 5000 | 2028-01-31 | 2026-09-15 | |
| SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD | Phase 2 | Not yet recruiting | Justin Ryder | 40 | 2027-05-01 | 2026-01-20 |
| Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis Dapagliflozin, Empagliflozin, Methotrexate - Rheumatoid Arthritis (RA) | Phase 2 | Not yet recruiting | Al-Azhar University | 90 | 2026-12-01 | 2026-10-08 |
| EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction) Empagliflozin - Breast Cancer, Supportive Care in Cancer | Phase 2 | Not yet recruiting | Virginia Commonwealth University | 10 | 2026-12-01 | 2026-10-20 |
| Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease Empagliflozin, Insulin, Insulin Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Wake Forest University Health Sciences | 30 | 2026-11-01 | 2026-09-30 |
| A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 36 | 2026-10-14 | 2026-10-15 |
| Cardioprotective Effect of Empagliflozin in Breast Cancer Patients Empagliflozin (EMPA), Metformin - Empgliflozin Cardioprotective Effect | Phase 3 | Not yet recruiting | Tanta University | 150 | 2026-10-01 | 2026-09-24 |
| Vascular Effects of SGLT2i in Non-diabetic CKD Empagliflozin, Placebo - Non-diabetic Chronic Kidney Disease | Phase 2 | Not yet recruiting | VA Office of Research and Development | 52 | 2026-10-01 | 2026-08-20 |
| Role of Finerenone in African American Veterans With Diabetic Kidney Disease Finerenone 10 MG, Empagliflozin 10 MG - Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Washington D.C. Veterans Affairs Medical Center | 30 | 2026-10-01 | 2026-08-21 |
| Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients empagliflozin, Placebo - ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI) | Phase 2 | Not yet recruiting | Rehman Medical Institute - RMI | 480 | 2026-09-01 | 2026-08-06 |
| The GranStone Trial empagliflozin (Jardiance) 25 mg, Losartan 100 mg - Paraffinoma, Granuloma, Foreign-Body | Phase 2 / Phase 3 | Not yet recruiting | Martin Blomberg Jensen | 100 | 2026-09-01 | 2026-09-18 |
| QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy empagliflozin, Finerenone, Mazdutide - Type 2 Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Huijie Zhang | 820 | 2026-09-01 | 2026-08-20 |
| Neurovascular Effects of Empagliflozin Empagliflozin (EMPA), Placebo - Blood Pressure, Endothelial Dysfunction | Phase 4 | Not yet recruiting | Kanokwan Bunsawat | 100 | 2026-09-01 | 2026-09-02 |
| Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 Empagliflozin 10 MG then Placebo, Placebo then Empagliflozin 10 MG - Chronic Kidney Diseases | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Nice | 34 | 2026-08-25 | 2026-09-10 |
| SGLT2i Therapy in Islet Transplantation (SIT) Empagliflozin 25 MG Oral Tablet, Empagliflozin 10 MG Oral Tablet [Jardiance] - Partial Islet Function, TPIAT | Phase 4 | Recruiting | University of Minnesota | 40 | 2026-07-21 | 2026-07-22 |
| Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial Empagliflozin and Finerenone, Placebo for Empagliflozin and Finerenone - Hypertension (HTN) | Not applicable | Not yet recruiting | Heart Health Research Center | 260 | 2026-07-13 | 2026-07-01 |
| Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention Empagliflozin 10 MG, Placebo, Personalized dietary counseling - Kidney Stone, Nephrolithiasis | Phase 3 | Recruiting | Insel Gruppe AG, University Hospital Bern | 400 | 2026-07-02 | 2026-08-03 |
| SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial Empagliflozin 10 mg, Placebo - Gout and Hyperuricemia | Phase 4 | Recruiting | Massachusetts General Hospital | 60 | 2026-07-01 | 2026-08-05 |
| SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD) SGLT2 Inhibitor, Standard Diabetes Care - Type 2 Diabetes Mellitus (T2DM), Cognitive Dysfunction | Not applicable | Active not recruiting | University of Primorska | 200 | 2026-06-20 | 2026-07-10 |
| Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets - Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2026-06-07 | 2026-10-13 |
Showing 20 of 525. Sign in to see all of them.
Diabetes Mellitus, Type 2 (191) · Diabetes Mellitus (50) · Heart Failure (50) · Renal Insufficiency, Chronic (26) · Non-alcoholic Fatty Liver Disease (20) · Obesity (19) · Hypertension (14) · Cardiovascular Diseases (13) · Diabetes Mellitus, Type 1 (13) · Diabetic Nephropathies (11) · Insulin Resistance (11) · Coronary Artery Disease (10) · Metabolic Syndrome (9) · Fatty Liver (7) · Kidney Failure, Chronic (7)
Boehringer Ingelheim (124) · Humanis Saglık Anonim Sirketi (9) · Tanta University (9) · The University of Texas Health Science Center at San Antonio (8) · Ain Shams University (7) · University Hospital, Basel, Switzerland (7) · Alexandria University (5) · Assiut University (5) · Brigham and Women's Hospital (5) · EMS (5) · National Taiwan University Hospital (5) · Yonsei University (5) · ADIUM (4) · Amsterdam UMC, location VUmc (4) · Getz Pharma (4)
United States (129) · Germany (88) · Canada (53) · South Korea (53) · Egypt (42) · Spain (39) · China (38) · Italy (37) · Japan (37) · United Kingdom (37) · Mexico (32) · India (31) · Poland (31) · France (30) · Denmark (29)
Ralph DeFronzo, MD (5) · Jeffrey Testani, MD (4) · Shirley Wang, PhD, ScM (3) · Carolina Solis-Herrera, MD (2) · Chih-Cheng Wu, MD. PhD (2) · Jacek Kubica, Prof. (2) · Justin Ryder, PhD (2) · Ka Shing Cheung, MD, MPH (2) · Manfred Hecking, MD (2) · Mikhail Kosiborod, MD (2) · Nattachai Srisawat (2) · Rehab H Werida, Ass Prof. (2) · Suzanne Craft, PhD (2)
PMID 35472672, PMID 38770818, PMID 31081589, PMID 23940010, PMID 27316632, PMID 34693515, PMID 23497760, PMID 26378978, PMID 28753486, PMID 30862658, PMID 32865377, PMID 39356039, PMID 42653697, PMID 15882287, PMID 24279801, PMID 24334175, PMID 24344941, PMID 24491572, PMID 25307034, PMID 28533501, PMID 30287422, PMID 31218819, PMID 31539565, PMID 32803882, PMID 33084149, PMID 33186500, PMID 34397263, PMID 34473343, PMID 35331406, PMID 35687107, PMID 36017745, PMID 36129693, PMID 37268640, PMID 37489818, PMID 37616393, PMID 37621153, PMID 38037709, PMID 38365073, PMID 38439582, PMID 38558314, PMID 39843293, PMID 40377984, PMID 40855136, PMID 41196655, PMID 42498959, PMID 11588337, PMID 11794168, PMID 11889147, PMID 12105309, PMID 15851648
2016 (12), 2017 (11), 2009 (10), 2023 (7), 2019 (5), 2025 (5), 2014 (4), 2015 (4), R01DK024092 (4), 2008 (2), 1OT2HL156812-01 (1), 2018 (1), DP3DK106785 (1), I01CX002859 (1), K23DK106520 (1)